| UHC Commercial Medical & Drug | Complement C5 Inhibitors – Commercial Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Enjaymo® (Sutimlimab-Jome) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Givlaari® (Givosiran) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Lemtrada® (Alemtuzumab) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Niktimvo™ (Axatilimab-Csfr) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Parsabiv® (Etelcalcetide) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| UHC Commercial Medical & Drug | Somatostatin Analogs – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026-04-01 |
| Medical Mutual | Adzynma® (ADAMTS13, recombinant-krhn) (Intravenous) | 2026-04-01 |
| Medical Mutual | Alpha-1-Proteinase Inhibitors: Aralast® NP (Intravenous) | 2026-04-01 |
| Medical Mutual | Brineura (cerliponase alfa) (Intraventricular) | 2026-04-01 |